Nuwaysir Named as Ensoma Chief Executive Officer
13 October 2021 - - US-based gene therapy company Ensoma has appointed Emile Nuwaysir, Ph.D., as president, chief executive officer and member of the company's board of directors, the company said.

In conjunction with the CEO appointment, Paula Soteropoulos, executive chairman of Ensoma, will transition to the role of chairman of the board, and Kush M. Parmar, M.D., Ph.D., managing partner of 5AM ventures, will continue to serve as a member of the board.

Dr. Nuwaysir is currently the chairman of the Alliance for Regenerative Medicine, an international advocacy organization comprised of 400+ member companies dedicated to advancing cell and gene medicines.

He joins Ensoma from BlueRock Therapeutics, an independently operated subsidiary of Bayer Pharmaceuticals, where he was CEO and continues to serve as chairman of the company's board of directors.

As the CEO of BlueRock from inception, he helped build a platform company at the intersection of cellular and genetic medicine, develop a pipeline of first-in-class therapeutic programs, and managed the company's acquisition and operation with Bayer.

Prior to BlueRock, Dr. Nuwaysir served as president and chief operating officer of Cellular Dynamics International, A Fujifilm company.

He played a leading role in growing CDI and its stem cell therapy efforts from its inception, including its early efforts as a pre-revenue startup, to its successful IPO on NASDAQ and ultimate acquisition by Fujifilm.

He was also president of Opsis Therapeutics Inc., CDI's retinal cell therapy subsidiary. Before CDI, Dr. Nuwaysir was the first employee of NimbleGen Systems, serving as a member of the senior management team that built a successful company and orchestrated a dual-track IPO process leading to the company's acquisition by Roche Diagnostics.

After the acquisition of NimbleGen, Dr. Nuwaysir served as chief technical officer of the Roche NimbleGen subsidiary.

Dr. Nuwaysir is also currently vice chairman of Invenra Inc., a multi-specifics antibody platform company he co-founded in 2011. He has held postdoctoral fellowships at the National Institutes of Health and the University of North Carolina at Chapel Hill.

Ensoma said its gene therapy platform is the first to precisely engineer any or all hematopoietic and immune cells with a one-time, off-the-shelf in vivo treatment.